In summary, re-engineering EPO as a BBB-penetrating IgG-EPO fusion protein enables neuroprotection in experimental PD with systemic administration of 1 mg/kg, and this dose causes only a minor increase in Hct, and no significant immune response. Here, EPO is linked to Parkinson disease.